Poland vs Saint Lucia: Statin use vs. average non-HDL cholesterol levels
Poland
3.5
in 2018
Saint Lucia
3.5
in 2018
Poland rank
52nd
Saint Lucia rank
52nd
Statin use vs. average non-HDL cholesterol levels over time
- Poland
- Saint Lucia
How they compare
Poland currently reports 3.5 against 3.5 in Saint Lucia, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Poland ahead.
Poland ranks 52nd and Saint Lucia ranks 52nd of 191 countries.
Poland has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Poland | Saint Lucia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.9 | 3.13 | 0.77 | Poland |
| 1990s | 3.9 | 3.2 | 0.7 | Poland |
| 2000s | 3.8 | 3.27 | 0.53 | Poland |
| 2010s | 3.59 | 3.42 | 0.1667 | Poland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Poland or Saint Lucia?
- Poland, at 3.5 against 3.5 in Saint Lucia as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Poland and Saint Lucia?
- 0, with Poland ahead.
- How many years of comparable data are there for Poland and Saint Lucia?
- 39 years are reported by both, from 1980 to 2018.
- How do Poland and Saint Lucia rank globally for statin use vs. average non-hdl cholesterol levels?
- Poland ranks 52nd and Saint Lucia ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.